Quarterly UpdatesNov 5, 2026, 06:26 AM
Innate Pharma: IPH4502 Data Presentation, Lacutamab Trial Update, €96.8M Cash
AI Summary
Innate Pharma SA reported its third quarter 2026 business and financial update. Key developments include upcoming presentations of Phase 1 data for IPH4502, progress in lacutamab trials with a planned FDA filing in H2 2027, and an expected readout for the AstraZeneca-led PACIFIC-9 Phase 3 trial in H1 2027. The company reported a cash position of €96.8 million as of September 30, 2026, with a cash horizon extending to Q1 2028. Additionally, Frédéric Lombard, CFO, will step down on December 31, 2026.
Key Highlights
- Phase 1 dose-escalation data for Nectin-4 ADC IPH4502 to be presented at ENA 2026 on November 18.
- Lacutamab Phase 3 TELLOMAK-3 trial to have first patient dosing in Q1 2027; FDA accelerated approval filing planned in H2 2027.
- AstraZeneca-led PACIFIC-9 Phase 3 trial readout expected in H1 2027.
- Cash position of €96.8 million as of September 30, 2026, with an anticipated cash horizon until the end of Q1 2028.
- Revenues for the first nine months of 2026 amounted to €3.4 million, up from €2.3 million in the same period of 2025.
Price Impact
More from IPHA